Pharmacokinetics of new oral hepatitis C antiviral drugs

Bibliography

• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-64
   PubMed Web of Science ®Google Scholar
• Hadziyannis S, Sette H, Morgan T, Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55
   PubMed Web of Science ®Google Scholar
• McHutchison J, Lawitz E, Shiffman M, Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93
   PubMed Web of Science ®Google Scholar
• Lamarre D, Anderson P, Bailey M, An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003;426:186-9
   PubMed Web of Science ®Google Scholar
• Lin C, Kwong A, Perni R. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006;6:3-16
   PubMedGoogle Scholar
• Perni R, Almquist S, Byrn R, Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2006;50:899-909
   PubMed Web of Science ®Google Scholar
• Lin K, Perni R, Kwong A, Lin C. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrob Agents Chemother 2006;50:1813-22
   PubMed Web of Science ®Google Scholar
• Reesink H, Zeuzem S, Weegink C, Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006;131:997-1002
   PubMed Web of Science ®Google Scholar
• Marcellin P, Forns X, Goeser T, Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011;140:459-68
   PubMed Web of Science ®Google Scholar
• Van Heeswijk R, Boogaerts G, Garg V, The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. Abstracts of the 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy; 23 – 24 June 2010; Boston, MA, USA
   Google Scholar
• Van Heeswijk R, Boogaerts G, De Backer K, The pharmacokinetic interaction between esomeprazole and the investigational HCV protease inhibitor telaprevir [abstract 11]. Abstracts of the 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy; 23 – 24 June 2010; Boston, MA, USA
   Google Scholar
• Garg V, Chandorkar G, Yang Y, The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir [abstract PK13]. Abstracts of the 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy; 22 – 23 June 2011; Cambridge, MA, USA
   Google Scholar
• Garg V, van Heeswijk R, Yang Y, The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir. J Clin Pharmacol 2011; In press
   Web of Science ®Google Scholar
• Luo X, van Heeswijk R, Alves K, The effect of telaprevir on the pharmacokinetics of alprazolam and zolpidem in healthy volunteers [abstract PK11]. Abstracts of the 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy; 22 – 23 June 2011; Cambridge, MA, USA
   Google Scholar
• Garg V, Chandorkar G, Farmer H, Effect of telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol 2011; In press
   Web of Science ®Google Scholar
• Lee J, van Heeswijk R, Alves K, Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother 2011;55:4569-74
   PubMed Web of Science ®Google Scholar
• Garg V, van Heeswijk R, Lee J, Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011;54:20-7
   PubMed Web of Science ®Google Scholar
• Van Heeswijk R, Vandevoorde A, Verboven P, The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir. Abstracts of the 46th EASL Annual Meeting, Berlin, 2011. Abstract 1244. J Hepatol 2011;54(Suppl 1):S491
   Web of Science ®Google Scholar
• Chakilam A, Chavan A, Smith G, Telaprevir binding to isolated human plasma proteins and protein binding displacement interactions between telaprevir and warfarin [abstract PK20]. Abstracts of the 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy; 22 – 23 June 2011; Cambridge, USA
   Google Scholar
• Seden K, Back D. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Curr Opin HIV AIDS 2011;6:514-26
   PubMed Web of Science ®Google Scholar
• Van Heeswijk R, Vandevoorde A, Boogaerts A, Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers [abstract 119]. Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections; 27 February – 2 March 2011; Boston, USA
   Google Scholar
• Sulkowski M, Dieterich D, Sherman K, New HIV and HCV antiviral agents, prevention, and ARV strategies [abstract 146LB]. Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections; 27 February – 2 March 2011; Boston, USA
   Google Scholar
• Kakuda T, Leopold L, Nijs S, Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: a randomised, two-way crossover trial [abstract 018]. Abstracts of the 13th Intl Workshop on Clinical Pharmacology of HIV Therapy; 16 – 18 April 2012; Barcelona, Spain
   Google Scholar
• Van Heeswijk R, Boogaerts G, Vandevoorde A, The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers [abstract LB A1-1738]. Abstracts of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 17 – 20 September 2011; Chicago, IL, USA
   Google Scholar
• Malcolm B, Liu R, Lahser F, SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006;50:1013-20
   PubMed Web of Science ®Google Scholar
• Victrelis1 (Boceprevir) US Prescribing Information, FDA. Available from: http://www.merck. com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf [Accessed 3 May 2012]
   Google Scholar
• Sarrazin C, Rouzier R, Wagner F, SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007;132:1270-8
   PubMed Web of Science ®Google Scholar
• Kaserra C, Hughes E, Treitel M, Clinical pharmacology of boceprevir: metabolism, excretion and drug-drug interactions [abstract 118]. Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections; 27 February – 2 March 2011; Boston, USA
   Google Scholar
• Hammond K, Wolfe P, Burton J, Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers [abstract 015]. Abstracts of the13th Intl Workshop on Clinical Pharmacology of HIV Therapy; 16 – 18 April 2012; Barcelona, Spain
   Google Scholar
• Hulskotte E, Feng H, Xuan F, Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir and darunavir [abstract 771LB]. Abstracts of the 19th Conference on Retroviruses and Opportunistic Infections; 5 – 8 March 2012; Seattle, USA
   Google Scholar
• Mallolas J, Pol S, Rivero A, Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV co-infected patients: end of treatment (week 48) interim results. Abstracts of the 47th EASL Annual Meeting; Barcelona, 2012; Abstract 50. J Hepatol 2012;56(Suppl 2):22
   Web of Science ®Google Scholar
• de Kanter C, Blonk M, Colbers A, The influence of the HCV protease inhibitor boceprevir on the pharmacokinetics of the HIV integrase inhibitor raltegravir [abstract 772LB]. Abstracts of the 19th Conference on Retroviruses and Opportunistic Infections; 5 – 8 March 2012; Seattle, USA
   Google Scholar
• Reesink H, Fanning G, Farha K, Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010;138:913-21
   PubMed Web of Science ®Google Scholar
• Lin T, Lenz O, Fanning G, In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 2009;53:1377-85
   PubMed Web of Science ®Google Scholar
• Fried M, Buti M, Dore G, Efficacy and safety of TMC 435 in combination with peginterferon-2a and ribavirin in treatment-naïve genotype-1 HCV patients: 24 week interim results from de PILLAR study. Hepatology 2010;52(Suppl 1):LB-5
   Google Scholar
• Moreno C, Berg T, Tanwandee T, A phase IIa, open-label study to assess the antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6 [abstract 895]. Abstracts of the 61st Annual Meeting of the American Association for the Study of Liver Diseases; October 29 – November 2 2010; Boston, USA
   Google Scholar
• Sekar V, Simion A, Peeters M, Pharmacokinetics of TMC435 in subjects with moderate hepatic impairment. Abstracts of the 46th EASL Annual Meeting, Berlin, 2011. Abstract 472. J Hepatol 2011;54(Suppl 1):193
   PubMed Web of Science ®Google Scholar
• Beaumont-Mauviel M, Simion A, De Smedt G, The pharmacokinetic interaction between the investigational HCV NS3/4A protease inhibitor TMC435 and escitalopram [abstract 1354]. Abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 4 – 8 November 2011; San Francisco, USA
   Google Scholar
• Beaumont-Mauviel M, De Smedt G, Peeters M, The pharmacokinetic interaction between the investigational NS3/4A HCV protease inhibitor TMC435 and methadone [abstract 1353]. Abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 4 – 8 November 2011; San Francisco, USA
   Google Scholar
• Ouwerkerk-Mahadevann S, Sekar V, Peeters M, The pharmacokinetic interactions of HCV protease inhibitor TMC435 with rilpivirine, tenofovir, efavirenz or raltegravir in healthy volunteers [abstract 49]. Abstracts of the 19th Conference on Retroviruses and Opportunistic Infections; 5 – 8 March 2012; Seattle, USA
   Google Scholar
• White P, Llinas-Brunet M, Amad M, Preclinical characterization of BI-201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother 2010;54:4611-18
   PubMed Web of Science ®Google Scholar
• Manns M, Bourliere M, Benhamou Y, Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011;54:1114-22
   PubMed Web of Science ®Google Scholar
• Sulkowski M, Ceasu E, Asselah T, SILEN-C1: sustained virologic response and safety of BI-201335 combined with peginterferon a-2a and ribavirin in treatment-naıve patients with chronic genotype 1 HCV infection. Abstracts of the 46th EASL Annual Meeting, Berlin, 2011. Abstract 60. J Hepatol 2011;54(Suppl 1):27
   Google Scholar
• Sulkowski M, Bourliere M, Bronowicki J, SILEN-C2: sustained virologic response and safety of BI-201335 combined with peginterferon a-2a and ribavirin (P/R) in chronic HCV genotype 1 patients with non-response to P/R. In: abstracts of the 46th EASL Annual Meeting, Berlin, 2011. Abstract 66. J Hepatol 2011. 54(Suppl 1): 30
   Google Scholar
• Soriano V, Gane E, Angus P, The efficacy and safety of the interferon-free combination of BI201335 and BI207127 in genotype 1 HCV patients with cirrhosis - interim analysis from SOUND-C2 [abstract 1420]. 47th EASL; 18 – 22 April 2012; Barcelona
   Google Scholar
• Sane R, Podila L, Mathur A, Mechanisms of isolated unconjugated hyperbilirubinaemia induced by the HCV NS3/4A protease inhibitor BI-201335. Abstracts of the 46th EASL Annual Meeting, Berlin, 2011. Abstract 1236. J Hepatol 2011. 54(Suppl 1):488
   Google Scholar
• Bressanelli S, Tomei L, Rey F, Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J Virol 2002;76:3482-92
   PubMed Web of Science ®Google Scholar
• Lee J, Nam I, Myung H. Nonstructural protein 5B of hepatitis C virus. Mol Cells 2006;21:330-6
   PubMed Web of Science ®Google Scholar
• Gane E, Stedman C, Hyland R, PSI-7977: ELECTRON. Interferon is not required for sustained virologic response in treatment-naive patients with HCV GT2 or GT3 [abstract 34]. Abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 5 – 8 November 2011; San Francisco, California
   Google Scholar
• Lawitz E, Lalezari J, Hassanein T, PROTON: PSI-7977 and pegIFN/RBV in treatment-naive patients with HCV GT1: sustained virologic response [abstract 225]. Abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 5 – 8 November 2011; San Francisco, California
   Google Scholar
• Lalezari J, Lawitz E, Rodriguez-Torres M, Once daily PSI-7977 plus pegIFN/RBV in a phase 2b trial: rapid virologic suppression in treatment-naive patients with HCV GT2/GT3. Abstracts of the 46th EASL Annual Meeting, Berlin, 2011. Abstract 61. J Hepatol 2011;54(Suppl 1):28
   Web of Science ®Google Scholar
• Cornpropst M, Denning J, Clemons D, The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977. Abstracts of the 47th EASL Annual Meeting, Barcelona, 2012. Abstract 1101. J Hepatol 2012;56(Suppl 2):S433
   PubMed Web of Science ®Google Scholar
• Denning J, Cornpropst M, Clenons D, Lack of effect of the nucleotide analog PSI-7977 an methadone pharmacokinetics and pharmacodynamics [abstract 372]. Abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 5 – 8 November 2011; San Francisco, California
   Google Scholar
• Soriano V, Sherman K, Rockstroh J, Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-coinfected patients. AIDS 2011;25:2197-208
   PubMed Web of Science ®Google Scholar
• Soriano V, Vispo E, Barreiro P. New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B. AIDS 2011;25:1013-14
   PubMed Web of Science ®Google Scholar
• Vispo E, Barreiro P, Pineda JA, Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008;13:429-37
   PubMed Web of Science ®Google Scholar
• Gao M, Nettles R, Belema M, Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010;465:96-100
   PubMed Web of Science ®Google Scholar
• Qiu D, Lemm J, O'Boyle D, The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization. J Gen Virol 2011;92:2502-11
   PubMed Web of Science ®Google Scholar
• Fridell R, Qiu D, Valera L, Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol 2011;85:7312-20
   PubMed Web of Science ®Google Scholar
• Nettles R, Gao M, Bifano M, Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011;54:1956-65
   PubMed Web of Science ®Google Scholar
• Bifano M, Sevinsky H, Persson A, Single-dose pharmacokinetics of daclatasvir (DCV; BMS-790052) in subjects with hepatic impairment compared with healthy subjects [abstract 1362]. Abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 5 – 8 November 2011; San Francisco, California
   Google Scholar
• Pol S, Ghalib R, Rustgi VK, High rates of SVR24 for BMS-790052, a NS5A replication complex inhibitor, in combination with Peg-IFNα-2A and ribavirin: phase 2a trial in treatment naive HCV-genotype 1 subjects [abstract H1-376]. Abstracts of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 17 – 20 September; Chicago, IL, USA; 2011
   Google Scholar
• Hezode C, Hirschfield G, Ghesquiere W, BMS-790052, a NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 patients: phase 2b AI444010 study interim week 12 results [abstract 227]. Abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 5 – 8 November 2011; San Francisco, California
   Google Scholar
• Sulkowski M, Gardiner D, Lawitz E, Potent viral suppression with all-oral combination of daclatasvir (NS5A Inhibitor) and GS-7977 (NS5B Inhibitor), +/-ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3. Abstracts of the 47th EASL Annual Meeting, Barcelona, 2012. Abstract 1422. J Hepatol 2012. 56(Suppl 2):560
   Google Scholar
• Suzuki F, Ikeda K, Toyota J, Dual oral therapy with the NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS-650032) in HCV genotype 1b-infected null responders or ineligible/intolerant to peginterferon. Abstracts of the 47th EASL Annual Meeting, Barcelona, 2012. Abstract 14. J Hepatol 2012. 56(Suppl 2): 7
   Google Scholar
• Lok A, Gardiner D, Lawitz E, Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366:216-24
   PubMed Web of Science ®Google Scholar
• Bifano M, Sevinsky H, Persson A, Daclatasvir (DCV; BMS-790052) has no clinically significant effect on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female subjects [abstract 1340]. Abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 5 – 8 November 2011; San Francisco, California
   Google Scholar
• Bifano C, Hwang C, Oosterhuis B, Assessment of HIV ARV drug interactions with the HCV NS5A replication complex inhibitor BMS-790052 demonstrates a pharmacokinetic profile that supports co-administration with tenofovir disoproxil fumarate, efavirenz, and atazanavir/ritonavir [abstract 618]. Abstracts of 19th Conference on Retroviruses and Opportunistic Infections; 5 – 8 March 2012; Seattle
   Google Scholar